Journal of Regenerative Medicine

Perspective

A SCITECHNOL JOURNAL

Next-Generation Immunotherapy: Targeting the Immune System for Cancer Treatment

Brian Jones*

Institute for Regeneration and Repair, University of Edinburgh, UK

***Corresponding author:** Brian Jones, Institute for Regeneration and Repair, University of Edinburgh, UK, E-mail: brian.j@ed.ac.uk

Citation: Jones B (2024) CRISPR and Beyond: The Evolving Landscape of Gene Therapy for Disease Correction. J Regen Med 13:5.

Received: 02-Sep-2024, Manuscript No. JRGM-24-148123, **Editor assigned:** 03-Sep-2024, PreQC No. JRGM-24-148123 (PQ), **Reviewed:** 17-Sep-2024, QC No. JRGM-24-148123, **Revised:** 23-Sep-2024, Manuscript No. JRGM-24-148123 (R), **Published:** 27-Sep-2024, DOI:10.4172/2325-9620.1000330

Introduction

Cancer treatment has traditionally relied on surgery, chemotherapy, and radiation, but in recent years, immunotherapy has emerged as a groundbreaking approach, harnessing the body's own immune system to combat cancer. The development of next-generation immunotherapies offers hope for more targeted, effective, and less toxic treatments. These therapies aim to enhance the immune system's natural ability to recognize and destroy cancer cells while minimizing harm to normal tissues [1].

Immunotherapy works by stimulating or enhancing the immune system's response to cancer. Unlike traditional treatments, which directly target the tumor, immunotherapy empowers the immune system to detect and eliminate cancer cells. The immune system is naturally capable of identifying and attacking abnormal cells, but cancer cells often develop mechanisms to evade immune detection. Next-generation immunotherapies are designed to overcome these barriers [2].

One of the most successful forms of immunotherapy to date has been immune checkpoint inhibitors. These drugs block the proteins that cancer cells use to suppress immune responses. Checkpoint proteins such as PD-1, PD-L1, and CTLA-4 act as "brakes" on immune cells, preventing them from attacking cancer. Inhibitors like pembrolizumab (Keytruda) and nivolumab (Opdivo) release these brakes, allowing the immune system to recognize and destroy cancer cells. These therapies have shown remarkable success in treating cancers like melanoma, lung cancer, and bladder cancer [3].

Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a revolutionary advance in immunotherapy. This technique involves extracting a patient's T cells, genetically modifying them to recognize specific cancer antigens, and then reinfusing them into the patient's body. CAR-T cells are equipped with receptors that allow them to target cancer cells directly. This therapy has shown remarkable efficacy in treating blood cancers, such as leukemia and lymphoma, with some patients achieving long-term remission [4].

T-cell receptor (TCR) therapy is another promising approach that involves engineering T cells to express receptors that recognize tumor-specific antigens. Unlike CAR-T therapy, which is primarily effective against blood cancers, TCR therapy is designed to target solid tumors by identifying specific peptides presented by cancer cells on major histocompatibility complexes (MHC). This approach is still in its experimental stages, but early results are encouraging, particularly for hard-to-treat cancers like melanoma and sarcomas [5].

Personalized cancer vaccines are designed to stimulate the immune system by introducing tumor-specific antigens. These vaccines are tailored to each patient's cancer, identifying unique mutations or neoantigens present in the tumor cells. By training the immune system to recognize these mutations, the vaccines help to generate a more robust and targeted immune response. Although still in the experimental phase, personalized vaccines show promise for treating a wide range of cancers [6].

Bispecific antibodies are engineered to bind to two different targets simultaneously. One arm of the antibody binds to a cancer cell, while the other binds to an immune cell, bringing them into close proximity and enhancing the immune response. This approach allows the immune system to more effectively target cancer cells while avoiding off-target effects. Bispecific antibodies are currently being tested in clinical trials for cancers like multiple myeloma and non-Hodgkin lymphoma, with promising results [7].

Despite the success of immunotherapies, many patients do not respond to these treatments, and some develop resistance over time. Next-generation immunotherapies are focused on overcoming this challenge. Researchers are investigating combination therapies, where immunotherapy is paired with traditional treatments like chemotherapy, radiation, or targeted therapies, to enhance the immune response. Additionally, identifying biomarkers that predict response to immunotherapy is an area of active research, allowing for more personalized treatment approaches [8].

The tumor microenvironment plays a crucial role in the success of immunotherapy. Cancer cells are surrounded by various immune cells, blood vessels, and signaling molecules that can either support or inhibit the immune response. Next-generation immunotherapies aim to modify the tumor microenvironment to make it more conducive to immune cell activity. For example, therapies targeting myeloid-derived suppressor cells or regulatory T cells, which dampen the immune response, are being developed to improve treatment outcomes [9].

Adoptive cell therapy involves extracting and expanding immune cells from a patient's body, then reinfusing them to fight cancer. In addition to CAR-T and TCR therapies, researchers are exploring the potential of natural killer (NK) cells and tumor-infiltrating lymphocytes (TILs) for cancer treatment. These cells have shown

promise in early trials, particularly for patients with advanced-stage cancers that have not responded to other therapies [10].

Conclusion

Next-generation immunotherapies represent a paradigm shift in cancer treatment, offering new hope for patients with previously untreatable cancers. By harnessing the power of the immune system, these therapies have the potential to provide long-lasting, durable responses with fewer side effects than traditional treatments. As research continues, the goal is to make immunotherapy accessible to more patients, ultimately transforming cancer care for future generations.

References

1. Advani R., Flinn I, Popplewell L, Forero A, Bartlett N L, et al. (2018) CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma. N Engl J Med;379(18):1711-21.
2. Akhurst, R. J. (2017). Targeting TGF-beta signaling for therapeutic gain. Cold Spring Harb Perspect Biol;9(10):a022301.
3. Andzinski L, Kasnitz N, Stahnke S, Wu C F, Gereke M, et al. (2016) Type IIFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int J Cancer;138(8):1982-93.
4. Barr T A, Heath A W (2001) Functional activity of CD40 antibodies correlates to the position of binding relative to CD154. Immunology;102(1):39-43.
5. Bao, Y., and Cao, X. (2011). Revisiting the protective and pathogenic roles of neutrophils: Ly-6G is key!. Eur. J. Immunol;41(9):2535-8.
6. Brown M H, Dustin M L (2019). Steering CAR T cells into solid tumors. N Engl J Med;380(3):289-91.
7. Chew V, Toh H C, Abastado J P (2012) Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol;2012(1):608406.
8. Davies M. (2014) New modalities of cancer treatment for NSCLC: focus on immunotherapy. CMAR 2014;63-75.
9. Faassen A E, Dalke D P, Berton M T, Warren W D, Pierce S K (1995) CD40-CD40 ligand interactions stimulate B cell antigen processing. Eur J Immunol;25(12):3249-55.
10. Guillerey C, Huntington N D, Smyth M J (2016) Targeting natural killer cells in cancer immunotherapy. Nat Immunol;17(9):1025-36.